Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 4/2010

01-04-2010 | Rapid Communication

Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women

Authors: Silvia Sterpone, Valeria Mastellone, Luca Padua, Flavia Novelli, Clarice Patrono, Tommaso Cornetta, Daniela Giammarino, Vittorio Donato, Antonella Testa, Renata Cozzi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2010

Login to get access

Abstract

Purpose

This study aimed to assess whether haplotypes in XRCC1 and SNPs in OGG1 and XRCC3 were associated with an increased risk of developing breast cancer (BC) and early adverse reactions after radiotherapy.

Methods

43 Italian breast cancer patients and 31 healthy controls were genotyped for XRCC1(−77T→C,194,399), OGG1-326 and XRCC3-241 by RFLP–PCR.

Results

XRCC1-77T→C, XRCC1-194, OGG1 and XRCC3 were not associated with BC. On the contrary, we found a significant association (p ≤ 0.05) between breast cancer occurrence and XRCC1-399. The haplotype (H3) containing the variant allele at codon 399, together with variant C allele in the promoter and wild-type G allele at codon 194 was associated with higher BC risk [p = 0.009, OR = 7.04(1.63–30)]. The probability for developing this tumor was also increased by the number of SNPs in different genes. We found a significantly higher BC risk in subjects with ≥3 SNPs [OR = 2.72 (0.99–7.39), p = 0.04].

Conclusion

In our study, the 399-Gln allele of XRCC1 increased significantly the risk of BC and it may act as a dominant allele [Arg/Arg vs. (Gln/Gln + Arg/Gln), OR = 4.67 (95% CI 1.65–13.23), p = 0.005]. The combination of variant alleles at codon 399 and in position −77 could affect XRCC1 protein activity, impairing genome integrity and promoting cancer occurrence. Also, the number of SNPs in several genes involved in BER and HRR mechanisms made higher the risk of sporadic BC. We can conclude that genetic variants in multiple repair pathways may have a joint or additive effect in cancer risk.
Literature
go back to reference Andreassen CN, Alsner J, Overgaard M, Overgaard J (2003) Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69:127–135CrossRefPubMed Andreassen CN, Alsner J, Overgaard M, Overgaard J (2003) Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69:127–135CrossRefPubMed
go back to reference Azria D, Ozsahin M, Kramar A et al (2008) Single nucleotide polymorphisms, apoptosis and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14:6284–6288CrossRefPubMed Azria D, Ozsahin M, Kramar A et al (2008) Single nucleotide polymorphisms, apoptosis and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14:6284–6288CrossRefPubMed
go back to reference Bishop DK, Ear U, Bhattacharyya A et al (1998) Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 273:21482–21488CrossRefPubMed Bishop DK, Ear U, Bhattacharyya A et al (1998) Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 273:21482–21488CrossRefPubMed
go back to reference Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98:1382–1396CrossRef Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98:1382–1396CrossRef
go back to reference Brem R, Cox DG, Chapot B et al (2006) The XRCC1−77T→C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 27:2469–2474CrossRefPubMed Brem R, Cox DG, Chapot B et al (2006) The XRCC1−77T→C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 27:2469–2474CrossRefPubMed
go back to reference Brenneman MA, Wagener BM, Miller CA et al (2002) XRCC3 controls the fidelity of homologous recombination: roles for XRCC3 in the late stages of recombination. Mol Cell 10:387–395CrossRefPubMed Brenneman MA, Wagener BM, Miller CA et al (2002) XRCC3 controls the fidelity of homologous recombination: roles for XRCC3 in the late stages of recombination. Mol Cell 10:387–395CrossRefPubMed
go back to reference Cornetta T, Festa F, Testa A, Cozzi R (2006) DNA damage repair and genetic polymorphisms: assessment of individual radiosensitivity and repair capacity. Int J Radiat Oncol Biol Phys 66:537–545PubMed Cornetta T, Festa F, Testa A, Cozzi R (2006) DNA damage repair and genetic polymorphisms: assessment of individual radiosensitivity and repair capacity. Int J Radiat Oncol Biol Phys 66:537–545PubMed
go back to reference Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103:209–217CrossRefPubMed Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103:209–217CrossRefPubMed
go back to reference Coughlin SS, Khoury MJ, Steinberg KK (1999) BRCA1 and BRCA2 gene mutations and risk of breast cancer: public health perspectives. Am J Prev Med 16:91–98CrossRefPubMed Coughlin SS, Khoury MJ, Steinberg KK (1999) BRCA1 and BRCA2 gene mutations and risk of breast cancer: public health perspectives. Am J Prev Med 16:91–98CrossRefPubMed
go back to reference Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMed Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMed
go back to reference De Ruyck K, Szaumkessel M, De Rudder I et al (2007) Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 631:101–110PubMed De Ruyck K, Szaumkessel M, De Rudder I et al (2007) Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 631:101–110PubMed
go back to reference Duell EJ, Wiencke JK, Cheng TJ et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965–971CrossRefPubMed Duell EJ, Wiencke JK, Cheng TJ et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965–971CrossRefPubMed
go back to reference Duell EJ, Millikan RC, Pittman GS et al (2001) Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 10:217–222PubMed Duell EJ, Millikan RC, Pittman GS et al (2001) Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 10:217–222PubMed
go back to reference Hao B, Wang H, Zhou K et al (2004) Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64:4378–4384CrossRefPubMed Hao B, Wang H, Zhou K et al (2004) Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64:4378–4384CrossRefPubMed
go back to reference Hao B, Miao X, Li Y et al (2006) A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 25:3613–3620CrossRefPubMed Hao B, Miao X, Li Y et al (2006) A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 25:3613–3620CrossRefPubMed
go back to reference Ho AY, Atencio DP, Peters S et al (2006) Genetic predictors of adverse radiotherapy effects: the Gene-PARE Project. Int J Radiat Oncol Biol Phys 65:646–655PubMed Ho AY, Atencio DP, Peters S et al (2006) Genetic predictors of adverse radiotherapy effects: the Gene-PARE Project. Int J Radiat Oncol Biol Phys 65:646–655PubMed
go back to reference Hu JJ, Smith TR, Miller MS et al (2002) Genetic regulation of ionization sensitivity and breast cancer risk. Environ Mol Mutagen 39:208–215CrossRefPubMed Hu JJ, Smith TR, Miller MS et al (2002) Genetic regulation of ionization sensitivity and breast cancer risk. Environ Mol Mutagen 39:208–215CrossRefPubMed
go back to reference Hu Z, Ma H, Lu D et al (2005) A promoter polymorphism (−77T→C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tabacco smoking. Pharmacogenet Genomics 15:457–463CrossRefPubMed Hu Z, Ma H, Lu D et al (2005) A promoter polymorphism (−77T→C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tabacco smoking. Pharmacogenet Genomics 15:457–463CrossRefPubMed
go back to reference Huang Y, Li L, Yu L (2009) XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis 24:331–339 Huang Y, Li L, Yu L (2009) XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis 24:331–339
go back to reference Lunn RM, Langlois RG, Hsieh LL et al (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557–2561PubMed Lunn RM, Langlois RG, Hsieh LL et al (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557–2561PubMed
go back to reference Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM (2002) Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 11:1054–1064PubMed Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM (2002) Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 11:1054–1064PubMed
go back to reference Monaco R, Rosal R, Dolan MA et al (2007) Conformational effects of a common codon 399 polymorphism on BRCT1 domain of the XRCC1 protein. Protein J 26:541–546CrossRefPubMed Monaco R, Rosal R, Dolan MA et al (2007) Conformational effects of a common codon 399 polymorphism on BRCT1 domain of the XRCC1 protein. Protein J 26:541–546CrossRefPubMed
go back to reference Moullan N, Cox DG, Angèle S et al (2003) Polymorphisms in the DNA repair gene XRCC1 m breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12:1168–1174PubMed Moullan N, Cox DG, Angèle S et al (2003) Polymorphisms in the DNA repair gene XRCC1 m breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12:1168–1174PubMed
go back to reference Parshad R, Price FM, Bohr VA et al (1996) Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 74:1–5PubMed Parshad R, Price FM, Bohr VA et al (1996) Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 74:1–5PubMed
go back to reference Saadat M, Kohan L, Omidvari S (2007) Genetic polymorphisms of XRCC1 (codon Arg 399Gln) and susceptibility to breast cancer in Iranian women, a case-control study. Breast Cancer Res Treat 111:549–553CrossRefPubMed Saadat M, Kohan L, Omidvari S (2007) Genetic polymorphisms of XRCC1 (codon Arg 399Gln) and susceptibility to breast cancer in Iranian women, a case-control study. Breast Cancer Res Treat 111:549–553CrossRefPubMed
go back to reference Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608PubMed Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608PubMed
go back to reference Smith TR, Miller MS, Lohman K et al (2003) Polymorphisms in XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 190:183–190CrossRefPubMed Smith TR, Miller MS, Lohman K et al (2003) Polymorphisms in XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 190:183–190CrossRefPubMed
go back to reference Takezaki T, Gao CM, Wu JZ et al (2002) hOGG1 Ser(326)Cys polymorphism and modification by environmental factors of stomach cancer risk in Chinese. Int J Cancer 99:624–627CrossRefPubMed Takezaki T, Gao CM, Wu JZ et al (2002) hOGG1 Ser(326)Cys polymorphism and modification by environmental factors of stomach cancer risk in Chinese. Int J Cancer 99:624–627CrossRefPubMed
go back to reference Taylor RM, Thistlethwaite A, Caldecott KW (2002) Central role for the XRCC1 BRCT I domain in mammalian DNA-single strand break repair. Mol Cell Biol 22:2556–2563CrossRefPubMed Taylor RM, Thistlethwaite A, Caldecott KW (2002) Central role for the XRCC1 BRCT I domain in mammalian DNA-single strand break repair. Mol Cell Biol 22:2556–2563CrossRefPubMed
go back to reference Thompson LH, West MG (2000) XRCC1 keeps DNA from getting stranded. Mutat Res 459:1–18PubMed Thompson LH, West MG (2000) XRCC1 keeps DNA from getting stranded. Mutat Res 459:1–18PubMed
go back to reference Tuimala J, Szekely G, Gundy S et al (2002) Genetic polymorphisms of DNA repair and xenobiotics metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 32:1003–1008CrossRef Tuimala J, Szekely G, Gundy S et al (2002) Genetic polymorphisms of DNA repair and xenobiotics metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 32:1003–1008CrossRef
go back to reference Vidal AE, Boiteux S, Hickson ID, Radicella JP (2001) XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein–protein interactions. EMBO J 20:6530–6539CrossRefPubMed Vidal AE, Boiteux S, Hickson ID, Radicella JP (2001) XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein–protein interactions. EMBO J 20:6530–6539CrossRefPubMed
go back to reference Zhang X, Moréra S, Bates PA et al (1998) Structure of an XRCC1 BRCT domain: a new protein-protein interaction module. EMBO J 17:6404–6411CrossRefPubMed Zhang X, Moréra S, Bates PA et al (1998) Structure of an XRCC1 BRCT domain: a new protein-protein interaction module. EMBO J 17:6404–6411CrossRefPubMed
go back to reference Zhang Y, Newcomb PA, Egan KM et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358CrossRefPubMed Zhang Y, Newcomb PA, Egan KM et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358CrossRefPubMed
Metadata
Title
Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women
Authors
Silvia Sterpone
Valeria Mastellone
Luca Padua
Flavia Novelli
Clarice Patrono
Tommaso Cornetta
Daniela Giammarino
Vittorio Donato
Antonella Testa
Renata Cozzi
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0791-1

Other articles of this Issue 4/2010

Journal of Cancer Research and Clinical Oncology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.